Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

  • There is currently no data for INDV

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
25th Jul 20257:00 amRNSIndivior Announces Completion of London Delisting
24th Jul 20253:52 pmRNSHolding(s) in Company
24th Jul 20258:34 amRNSHolding(s) in Company
23rd Jul 20258:08 amRNSHolding(s) in Company
21st Jul 20254:23 pmRNSHolding(s) in Company
21st Jul 20258:33 amRNSHolding(s) in Company
18th Jul 20258:35 amRNSHolding(s) in Company
17th Jul 20252:00 pmRNSNotice of Results
1st Jul 20258:46 amRNSHolding(s) in Company
1st Jul 20258:43 amRNSHolding(s) in Company
1st Jul 20258:37 amRNSHolding(s) in Company
1st Jul 20258:34 amRNSHolding(s) in Company
1st Jul 20257:49 amRNSTotal Voting Rights
30th Jun 20257:00 amRNSIndivior Announces Inclusion in US Russell Indexes
25th Jun 20257:00 amRNSIndivior Appoints Tony Kingsley to the Board
17th Jun 20254:42 pmRNSHolding(s) in Company
13th Jun 20258:10 amRNSDirector/PDMR Shareholding - Correction
12th Jun 20254:24 pmRNSDirector/PDMR Shareholding
10th Jun 20254:12 pmRNSHolding(s) in Company
6th Jun 20254:49 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSIndivior Announces Intent to Cancel LSE Listing
15th May 20253:30 pmRNSDirector/PDMR Shareholding
13th May 20253:00 pmRNSIndivior to Participate in Upcoming Events
9th May 20254:37 pmRNSAmendment to Result of AGM
8th May 20252:31 pmRNSBlock listing Interim Review
8th May 20252:00 pmRNSResult of AGM
6th May 20251:48 pmRNSDirector/PDMR Shareholding
1st May 20259:21 amRNSTotal Voting Rights
24th Apr 20257:00 amRNS1st Quarter Results
22nd Apr 20251:58 pmRNSHolding(s) in Company
10th Apr 20254:51 pmRNSNotice of Results
3rd Apr 202512:31 pmRNSHolding(s) in Company
1st Apr 202511:19 amRNSTotal Voting Rights
28th Mar 20258:33 amRNSHolding(s) in Company
27th Mar 20252:00 pmRNSNotice of AGM
21st Mar 20253:40 pmRNSHolding(s) in Company
17th Mar 20251:25 pmRNSDirector/PDMR Shareholding
17th Mar 20251:17 pmRNSAnnual Financial Report
14th Mar 20253:44 pmRNSDirector/PDMR Shareholding
14th Mar 202510:03 amRNSHolding(s) in Company
11th Mar 202512:41 pmRNSDirector/PDMR Shareholding
11th Mar 202510:18 amRNSDirector/PDMR Shareholding
10th Mar 20255:39 pmRNSDirector/PDMR Shareholding
5th Mar 20252:02 pmRNSDirector/PDMR Shareholding
4th Mar 20251:45 pmRNSHolding(s) in Company
4th Mar 202511:23 amRNSDirector/PDMR Shareholding
4th Mar 202511:23 amRNSHolding(s) in Company
4th Mar 20257:00 amRNSFurther Changes to Board of Directors
4th Mar 20257:00 amRNSIndivior PLC Files 2024 Annual Report on Form 10-K
3rd Mar 20259:29 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.